Abbonarsi

Scalp involvement in patients referred for patch testing: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 1996 to 2016 - 10/03/21

Doi : 10.1016/j.jaad.2020.08.046 
Erin M. Warshaw, MD, MS a, b, c, Sara A. Kullberg, BA a, c, d, , Joel G. DeKoven, MD e, Howard I. Maibach, MD f, Donald V. Belsito, MD g, Jonathan I. Silverberg, MD h, Joseph F. Fowler, MD i, Amber R. Atwater, MD j, Denis Sasseville, MD k, Margo J. Reeder, MD l, James S. Taylor, MD m, Vincent A. DeLeo, MD n, Melanie D. Pratt, MD o, Kathryn A. Zug, MD p, Anthony F. Fransway, MD q
a Department of Dermatology, Park Nicollet Health Services, Minneapolis, Minnesota 
b Department of Dermatology, University of Minnesota, Minneapolis, Minnesota 
c Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota 
d University of Minnesota Medical School, Minneapolis, Minnesota 
e Division of Dermatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada 
f Department of Dermatology, University of California, San Francisco, California 
g Department of Dermatology, Columbia University Irving Medical Center, New York, New York 
h Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia 
i Division of Dermatology, University of Louisville, Louisville, Kentucky 
j Department of Dermatology, Duke University, Durham, North Carolina 
k Division of Dermatology, Montreal General Hospital, McGill University, Montreal, Quebec, Canada 
l Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 
m Department of Dermatology, Cleveland Clinic, Cleveland, Ohio 
n Department of Dermatology, Keck School of Medicine, Los Angeles, California 
o Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada 
p Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 
q Associates in Dermatology, Fort Myers, Florida 

Correspondence to: Sara A. Kullberg, BA, Park Nicollet Contact Dermatitis Clinic, 7550 34th Ave S, Ste 101, Minneapolis, MN 55450.Park Nicollet Contact Dermatitis Clinic7550 34th Ave S, Ste 101MinneapolisMN55450

Abstract

Background

Scalp conditions are often multifactorial.

Objective

To characterize patients with scalp involvement and patch-testing outcomes.

Methods

Retrospective cross-sectional analysis of North American Contact Dermatitis Group data (1996-2016). Study groups included patients with scalp involvement (≤3 anatomic sites coded) with or without additional sites.

Results

A total of 4.8% of patients (2331/48,753) had scalp identified as 1 of up to 3 affected anatomic sites. Approximately one-third of “scalp-only” individuals had a specific primary diagnosis of allergic contact dermatitis (38.6%), followed by seborrheic dermatitis (17.2%) and irritant contact dermatitis (9.3%). When adjacent anatomic sites were affected, allergic contact dermatitis was more frequently identified as the primary diagnosis (>50%). The top 5 currently clinically relevant allergens in scalp-only patients were p-phenylenediamine, fragrance mix I, nickel sulfate, balsam of Peru, and cinnamic aldehyde. Methylisothiazolinone sensitivity was notable when adjacent anatomic sites were involved. The top 3 specifically identified sources for scalp-only allergens were hair dyes, shampoo/conditioners, and consumer items (eg, hair appliances, glasses).

Limitations

Tertiary referral population.

Conclusion

Isolated scalp involvement was less likely to be associated with allergic contact dermatitis than when adjacent anatomic sites were involved. Overlap with multiple diagnoses was frequent, including seborrheic dermatitis, irritant dermatitis, other dermatoses, or all 3. p-Phenylenediamine was the most common allergen.

Il testo completo di questo articolo è disponibile in PDF.

Key words : allergic contact dermatitis, dermatitis, irritant contact dermatitis, itch, North American Contact Dermatitis Group, patch testing, p-phenylenediamine, pruritus, scalp, seborrheic dermatitis


Mappa


 Funding sources: None.
 Conflicts of interest: None disclosed.
 IRB approval status: Approved by Minneapolis Veterans Administration Medical Center's Subcommittee on Human Studies.
 This work was supported by the use of facilities and resources of the Minneapolis Veterans Affairs Medical Center. The contents do not represent the views of the US Department of Veterans Affairs or the US government.


© 2020  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 84 - N° 4

P. 977-988 - aprile 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Contact dermatitis associated with preservatives: Retrospective analysis of North American Contact Dermatitis Group data, 1994 through 2016
  • Amber Reck Atwater, Amy J. Petty, Beiyu Liu, Cynthia L. Green, Jonathan I. Silverberg, Joel G. DeKoven, Donald V. Belsito, Margo J. Reeder, Denis Sasseville, James S. Taylor, Howard I. Maibach, Matthew J. Zirwas, James G. Marks, Kathryn A. Zug, Joseph F. Fowler, Melanie D. Pratt, Vincent A. DeLeo, Erin M. Warshaw
| Articolo seguente Articolo seguente
  • Hand dermatitis in adults referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2000 to 2016
  • Jonathan I. Silverberg, Erin M. Warshaw, Amber R. Atwater, Howard I. Maibach, Kathryn A. Zug, Margo J. Reeder, Denis Sasseville, James S. Taylor, Joseph F. Fowler, Melanie D. Pratt, Anthony F. Fransway, Matthew J. Zirwas, Donald V. Belsito, James G. Marks, Vincent A. DeLeo, Joel G. DeKoven

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.